Q4 / FY 2023 Results | February 22, 2024 This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding the Indivior Group's financial guidance including operating and profit margins for 2024 and its medium- and long-term growth outlook; assumptions regarding expected changes in market share and expectations regarding the extent and impact of competition; assumptions regarding future exchange rates; strategic priorities, s ...

Financial Performance - FY 2023 total net revenue increased by 21% to $1,093 million, with Q4 2023 net revenue up 22% to $293 million[8] - Adjusted operating profit for FY 2023 rose by 27% to $269 million, while Q4 2023 adjusted operating profit increased by 65% to $66 million[19] - FY 2023 net income was $2 million, a significant improvement from a net loss of $53 million in FY 2022; Q4 2023 net income was $54 million compared to a net loss of $183 million in Q4 2022[8] - Adjusted net income for FY 2023 increased by 32% to $223 million, with Q4 2023 adjusted net income rising by 56% to $61 million[8] - Q4 2023 operating profit was reported at $60 million, a significant improvement from a loss of $258 million in Q4 2022, with adjusted operating profit increasing 65% to $66 million[20] - FY 2023 reported net income was $2 million, while adjusted net income rose to $223 million, reflecting a 32% increase from FY 2022 adjusted net income of $169 million[25] - Q4 2023 diluted earnings per share were $0.38 on a reported basis and $0.43 on an adjusted basis, compared to a loss of $(1.34) per share in Q4 2022[26] - Basic earnings per share for FY 2023 was $0.01, a recovery from a loss of $0.38 in FY 2022[68] - Adjusted diluted earnings per share for FY 2023 improved, reflecting the positive trend in adjusted net income[144] Revenue Breakdown - SUBLOCADE net revenue for FY 2023 reached $630 million, reflecting a 54% increase year-over-year, with Q4 2023 net revenue of $176 million, up 49%[8] - Net revenue for Q4 2023 was $293 million, a 21.6% increase from $241 million in Q4 2022, and for FY 2023, it reached $1,093 million, up 21.4% from $901 million in FY 2022[41] - SUBLOCADE® revenue for Q4 2023 was $176 million, up 49% from $118 million in Q4 2022, and FY 2023 revenue was $630 million, a 54% increase from $408 million in FY 2022[57] Expenses and Costs - R&D expenses for FY 2023 increased by 47% to $106 million, driven by post-marketing studies and capacity expansion activities[16] - Selling, general, and administrative expenses for FY 2023 totaled $811 million, up from $763 million in FY 2022, driven by increased legal provisions and commercial investments[60] - The total exceptional items and adjustments in cost of sales for FY 2023 amounted to $8 million, compared to none in FY 2022[143] - Exceptional items and adjustments in selling, general and administrative expenses decreased from $302 million in FY 2022 to $268 million in FY 2023[143] Cash Flow and Investments - Cash and investments totaled $451 million at the end of 2023, down from $991 million in FY 2022, primarily due to litigation settlements and the Opiant acquisition[8] - Cash used in operations for FY 2023 was $292 million, a significant decline from cash provided by operations of $63 million in FY 2022[29] - FY 2023 cash outflow from investing activities was $98 million, including $124 million for the Opiant acquisition[30] - Cash and cash equivalents decreased to $316 million at the end of FY 2023 from $774 million at the end of FY 2022, reflecting a net cash outflow from operating activities of $315 million[46] Acquisitions and Assets - The company acquired 100% of Opiant Pharmaceuticals, Inc. in March 2023, which has been accounted for as an asset acquisition[50] - The acquisition of Opiant contributed $126 million to marketed products, reflecting the recognition of intangible assets[73] - The Group acquired an aseptic manufacturing facility for $5 million in cash and assumed certain contract manufacturing obligations, recognized as a business combination[123][124] - Goodwill of $5 million was recognized from the acquisition of the manufacturing facility, primarily due to Indivior-specific synergies[129] Shareholder Actions - The company initiated a third share repurchase program of up to $100 million, with approximately $42 million spent by February 16, 2024[10] - A share repurchase program commenced on November 17, 2023, with an aggregate purchase price of up to $100 million, and 1,413 thousand shares were repurchased by December 31, 2023[114] - The total cost of share repurchases during the period was $33 million, compared to $90 million in FY 2022[116] Taxation - The effective tax rate for FY 2023 was -100% due to minimal profit before taxation, with an adjusted tax expense of $51 million and an effective tax rate of 19%[22] - The effective tax rate for FY 2023 was impacted by an increase in the U.K. tax rate to 25%, resulting in a total tax benefit of $1 million, down from $42 million in FY 2022[62] - The tax on exceptional items and other adjustments for FY 2023 was $63 million, compared to $57 million in FY 2022[143] Legal and Regulatory Matters - The principal risks facing the Group have remained broadly unchanged, with increased commercialization risks due to competition in the opioid treatment market[32] - Indivior Inc. is named in over 400 civil lawsuits related to opioid marketing practices, with most cases consolidated in the Opioid MDL in Ohio[105] - The Group has been named in more than 30 lawsuits regarding tooth damage claims related to SUBOXONE products, which are in preliminary stages[108] - Humana, Inc. filed a complaint in Kentucky on August 20, 2021, with similar claims as in the Antitrust MDL, and the court lifted a stay on October 30, 2023[105] Financial Position - Total assets increased to $1,954 million as of December 31, 2023, from $1,769 million as of December 31, 2022, driven by growth in intangible assets and trade receivables[43] - Current liabilities rose to $1,305 million at the end of FY 2023, up from $1,019 million in FY 2022, primarily due to an increase in provisions[43] - Net working capital was negative $347 million as of December 31, 2023, compared to negative $283 million at the end of FY 2022[28] - The Group's total provisions increased to $419 million in 2023 from $308 million in 2022, driven by antitrust and other legal matters[84]

• INDV 2000 (OUD3): Phase 1 study MAD6 LSLV in Q3-2023, Successful endof-Phase 1 meeting with FDA in Q4- 20235 • INDV 4002 (AUD3): Phase 2 data Q4- 20235 Q3 2023 financial highlights Key Takeaways (vs. Q3 2022) ➤ Reported SG&A expenses driven by litigation provision; Adjusted SG&A expenses up 33% reflecting increased legal costs, Opiant and OPVEE launch expenses, SUBLOCADE commercial investments and cost inflation 2 See reconciliation pages in the appendix 3 Actual FX (foreign exchange) rates Cash & Borrowi ...

November 9, 2023 Strong Top-line Performance and Strategic Progress in Q3 2023 • FY 2023 SUBLOCADE NR now expected to be $610m to $630m (vs. $590m to $630m) • OPVEE® launched; U.S. Biomedical Advanced Research and Development Authority (BARDA) contract secured Period to September 30th (Unaudited) Q3 2023 $m Q3 2022 $m % Change YTD 2023 $m YTD 2022 $m % Change Net Revenue 271 232 17% 800 659 21% Operating (Loss)/Profit (183) 56 NM (65) 173 NM Net (Loss)/Income (135) 41 NM (52) 130 NM Diluted (LPS)/EPS ($) $( ...

Indivior PLC (INVVY) Q2 2023 Earnings Conference Call July 27, 2023 8:00 AM ET Company Participants Jason Thompson - Vice President of Investor Relations Mark Crossley - Chief Executive Officer Christian Heidbreder - Chief Scientific Officer Ryan Preblick - Chief Financial Officer Conference Call Participants James Vane-Tempest - Jefferies Max Herrmann - Stifel Paul Cuddon - Numis Securities Thibault Boutherin - Morgan Stanley Karl Burns - Northland Capital Markets Edward Thomason - Liberum Peter Testa - On ...

Q2/H1 2023 Results July 27, 2023 Important cautionary statement regarding forward-looking statements 2 This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding: expectations regarding the cost to resolve the Group's legal proceedings and regulatory matters; strategies for value creation and operational goals; expected sales levels for particular products; product development pipeline and potential future products; ex ...

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated by the Market Abuse Regulation (EU) No.596/2014, as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). Upon the publication of this announcement, the inside information is now considered to be in the public domain. July 27, 2023 Strong H1 and Q2 2023 Financial Results; FY 2023 Guidance Raised • Q2 2023 SUBLOCADE® Net Revenue (NR) of $155m, +58% versus ...

Thank you for taking my questions. Three, please. The first one on litigation. The press release mentioned that new offers and demands have been exchanged with the state in the context of the MDL litigation. So just curious to know why the states have been singled out here? What about the other classes of [indiscernible] purchasers and payers, which are also involved in the MDL? Is there any reason why they have been excluded from these additional exchanges? So that's the first question. Second one, on the ...

Important cautionary statement regarding forward-looking statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding the Indivior Group's financial guidance for 2023 and its medium- and long-term growth outlook; strategies for value creation; expectations for sales levels for particular products; expectations regarding the cost to resolve the Group's legal proceedings and regulatory matters; the timing of our ...

Conference Call Participants I would now like to hand the conference over to your host today, Jason Thompson. Please go ahead. Mark Crossley Touching briefly on our fiscal year 2023 guidance, we expect to deliver another year of attractive profitable growth. Ryan will take you through the details in a few minutes but I would highlight that we do plan to deliver top line growth and positive operating leverage in 2023, consistent with the medium-term financial outlook we We have participated in very early-sta ...